Clinical Trials in Nashville

Showing 4261-4280 of 20,298 trials

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

NCT05654532

This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699

Breast Cancer

Accutar Biotechnology Inc100 participantsStarted Dec 2022

Denver, Colorado, United States • Orlando, Florida, United States • Sarasota, Florida, United States +6 more locations

RECRUITINGPhase 2< 1 mile

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

NCT05296070

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.

Marginal Zone Lymphoma

University of Miami50 participantsStarted Jun 2022

Duarte, California, United States • Miami, Florida, United States • Atlanta, Georgia, United States +1 more locations

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Find Trials by Condition in Nashville

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Goal-Directed Sedation in Mechanically Ventilated Infants and Children

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

AngelMed Guardian® System PMA Post Approval Study

Pediatric Dose Optimization for Seizures in Emergency Medical Services

Edwards CLASP TR EFS

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod

The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial